Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SGX:T14)

Market Cap	4.08B
Revenue (ttm)	1.24B
Net Income (ttm)	410.38M
Shares Out	n/a
EPS (ttm)	0.53
PE Ratio	9.94
Forward PE	n/a
Dividend	0.21 (8.56%)
Ex-Dividend Date	Jul 2, 2024

Volume	57,100
Average Volume	114,750
Open	2.500
Previous Close	2.490
Day's Range	2.480 - 2.520
52-Week Range	1.990 - 2.660
Beta	n/a
RSI	64.78
Earnings Date	Aug 15, 2025

About SGX:T14

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, together with its subsidiaries, produces and sells traditional Chinese medicine, western medicine, and other products primarily in the People’s Republic of China. The company manufactures and sells of biochemical pharmaceutical products. It also engages in research and development of chinese patent medicines, chemical raw materials and preparations, and nutritional supplements. In addition, the company is involved in pharmaceutical and drug retail business. Further, it offers Suxiao ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1981
• Employees: 4,619
• Stock Exchange: Singapore Exchange
• Ticker Symbol: T14

Financial Performance

In 2024, SGX:T14's revenue was 7.31 billion, a decrease of -11.14% compared to the previous year's 8.22 billion. Earnings were 2.23 billion, an increase of 125.94%.

Financial numbers in CNY